We’re thrilled to announce that Digistain® is now available to over 60% of UK private patients, with reimbursement available though Bupa, WPA Health Insurance & Healix.
Tim Woodman, Medical Director at Bupa’s Policy and Cancer Services, said:
“I’m really excited to be working with Digistain. The agreement gives Bupa’s breast cancer customers access to a cutting-edge, effective and sustainable diagnostic technology that will have a real impact on providing the most effective care. It’s a good example of Bupa’s continuing commitment to be innovators in cancer care.”
